论文部分内容阅读
目的观察干扰素联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法入选病例随机分成两组,治疗组(干扰素加化疗组)22例与对照组(单纯化疗组)21例的疗效作对比。结果治疗组总有效率(CR+PR)为90.91%,对照组CR+PR为80.95%,两组对比差异有统计学意义(P<0.05)。结论干扰素联合化疗治疗NSCLC的临床疗效较显著。
Objective To observe the clinical efficacy of interferon combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Selected cases were randomly divided into two groups, the treatment group (interferon plus chemotherapy group) 22 cases compared with the control group (chemotherapy alone group) 21 cases of efficacy for comparison. Results The total effective rate (CR + PR) was 90.91% in the treatment group and 80.95% in the control group. The difference between the two groups was statistically significant (P <0.05). Conclusion Interferon combined with chemotherapy in the treatment of NSCLC clinical effect is more significant.